On November 21, 2025, BTIG reiterated coverage of Haemonetics (NYSE:HAE) with a Buy recommendation.
As of November 17, 2025, the average one-year price target for Haemonetics is $88.03/share. The forecasts range from a low of $75.75 to a high of $113.40. The average price target represents an increase of 17.18% from its latest reported closing price of $75.12 / share.
The projected annual revenue for Haemonetics is 1,270MM, a decrease of 4.36%. The projected annual non-GAAP EPS is 4.41.
https://www.nasdaq.com/articles/btig-reiterates-haemonetics-hae-buy-recommendation
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.